CCM
KROS icon

Consonance Capital Management’s Keros Therapeutics KROS Stock Holding History

Consonance Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-887,885
Closed -$37.7M – 21
2021
Q2 		$37.7M Sell
887,885
-2,324
-0.3% -$126K 4.54% 7
2021
Q1 		$54.8M Buy
890,209
+333,114
+60% +$21.1M 5.84% 5
2020
Q4 		$39.3M Buy
+557,095
New +$35.1M 3.67% 11

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Consonance Capital Management's KROS Position: Q3 2021 in Review

Consonance Capital Management sold out of Keros Therapeutics (KROS) in Q3 2021, closing a stake of 887,885 shares — an estimated $37.7M sold.

Consonance Capital Management first reported a position in KROS in Q4 2020 and held it in 3 quarters. The position peaked at $54.8M in Q1 2021. 88 funds tracked by Wall St. Rank hold KROS as of Q3 2021.

  • Consonance Capital Management reported no remaining Keros Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Consonance Capital Management sold 887,885 Keros Therapeutics shares in Q3 2021, an estimated $37.7M.
  • Consonance Capital Management first reported a position in Keros Therapeutics in Q4 2020 and held it in 3 quarters.
  • Consonance Capital Management's Keros Therapeutics position peaked at $54.8M in Q1 2021.
  • 88 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2021.

Based on Consonance Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.